The characteristics of patients frequently tested and repeatedly infected with *Chlamydia trachomatis* in Southwest Limburg, the Netherlands

Juliën N. A. P. Wijers¹²*, Nicole H. T. M. Dukers-Muijers¹², Christian J. P. A. Hoebe¹², Petra F. G. Wolffs¹ and Geneviève A. F. S. van Liere¹²

**Abstract**

**Background:** Repeat *Chlamydia trachomatis* (CT) infections are common. To better understand the characteristics of patients frequently infected with CT at our sexually transmitted infection (STI) care services, we assessed the differences between patients repeatedly infected with CT and those who repeatedly tested negative.

**Methods:** In this cross-sectional analysis of cohort data, we assessed individuals tested for CT at different STI care providers between 2011 and mid-2018 in Southwest Limburg, the Netherlands (n = 17,616). Patients with ≥2 repeat CT infections in the study period were categorized as “patients with repeat CT infections.” Multivariable logistic regression analyses were performed for the binary outcome measure: patients with repeat CT infections versus patients who repeatedly tested negative (reference group). Additional analyses were performed for only the STI clinic population.

**Results:** Patients aged < 25 years (OR: 1.83; 95%CI: 1.38–2.43), co-infected with HIV (OR: 2.07; 95%CI: 1.02–4.22) or co-infected with *Neisseria gonorrhoeae* (NG) (OR: 5.04; 95%CI: 3.33–7.63) had more repeat CT infections. In additional analyses among exclusively STI clinic visitors, patients with urogenital symptoms (OR: 2.17; 95%CI: 1.41–3.35), and patients notified for STIs (OR: 4.55; 95%CI: 3.17–6.54) had more frequent repeat CT infections.

**Conclusions:** Patients aged < 25 years and patients coinfected with HIV or NG had more frequent repeat CT infections, accounting for ~ 20% of the diagnosed CT infections. These patients are likely at the highest risk for transmitting and acquiring CT. Therefore, testing and retesting this group remains important to enhance CT control.

**Keywords:** Chlamydia, Sexually transmitted infections, Epidemiology, General practice, STI clinic, Repeat infection, Retesting

* Correspondence: julien.wijers@ggdzl.nl
  ¹Department of Social Medicine and Medical Microbiology, Care and Public Health Research Institute (CAPHRI), Maastricht University Medical Center (MUMC+), PO Box 5800, 6202, AZ, Maastricht, the Netherlands
  ²Department of Sexual Health, Infectious Diseases and Environmental Health, South Limburg Public Health Service, PO Box 33, 6400, AA, Heerlen, the Netherlands

© The Author(s). 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Background

*Chlamydia trachomatis* (CT) is a highly common bacterial sexually transmitted infection (STI) worldwide [1]. All patients who test positive for CT should be retested within three to twelve months, according to international testing guidelines [2–4]. It has been shown that up to 32% of the CT patients test positive again within 1 year after diagnosis [5–7].

According to the literature, factor associated with repeat CT infections within 1 year are: having multiple sexual partners, being a woman, patients with a younger age, and coinfection with other STIs, such as *Neisseria gonorrhoeae* (NG) [8–12]. These studies compared the characteristics of patients with one repeat infection to those of patients with no repeat infections. To date, it is unknown whether the characteristics of patients with more than one repeat CT infection over several years differ from those of patients who repeatedly tested negative for CT [9]. Differences in characteristics between patients repeatedly infected with CT and those who repeatedly tested negative for CT could indicate different high-risk populations. However, similarities in the characteristics between these groups could indicate similar sexual networks and high-risk behaviors [13, 14]. Furthermore, the extent to which patients repeat infections account for the total number of diagnosed CT infections could provide insight into CT transmission routes [9]. In an earlier publication, we showed that patients repeatedly infected with NG were mainly men who had sex with men (MSM), HIV positive, CT positive, and diagnosed by the STI clinic [15]. For CT, this could be different since NG mainly affects MSM, whereas CT affects the general population of men, women, and young people (aged < 25 years) [16].

Here, we compared the socio-demographic characteristics of patients with repeat CT infections to patients who repeatedly tested negative for CT. To achieve this, we performed this cross-sectional analysis of cohort data including all CT consultations of different STI care providers in a defined geographical area.

Methods

Study design and study setting

In this cross-sectional analysis of cohort data, all CT test consultations (*n* = 27,026) of 17,616 patients aged between 15 and 64 years were obtained from the database of the regional Medical Microbiology Laboratory of the Maastricht University Medical Center (MUMC+) between January 2011 to July 2018 (Fig. 1).

Population and sample size

The database included consultations from all STI care providers of three municipalities (Maastricht, Eijsden-Margraten, and Valkenburg aan de Geul) in the southwestern part of Limburg, the Netherlands. The STI care providers were: mental healthcare facilities (*n* = 178; 0.7%), the STI clinic (*n* = 12,170; 45.0%), the hospital (*n* = 3667; 13.6%), and GPs (*n* = 11,011; 40.7%). In the study area, 81% (*n* = 48) GPs sent CT samples for testing to the regional laboratory, ensuring sufficient laboratory coverage [7]. Samples tested positive for CT within 30 days of a previous positive CT test were excluded due to possible false-positive results [4] (*n* = 233). The vast majority of excluded tests (86.7%; 202/233) were diagnosed within 14 days of a previous CT infection. The study area included 111,162 inhabitants (hereafter referred to as the “residential population”) aged between 15 and 64 years (Statistics Netherlands: https://www.cbs.nl/en-gb).

We calculated the proportion of residents who were tested for CT once, and repeatedly infected with CT.

Data management

The dataset was aggregated on a patient level. This means that every patient occurred once in the dataset and all repeat tests and CT infections were added up per patient. Patients who had ≥2 CT infections in the entire study period were classified as “patients with repeat CT infections” (*n* = 244). The majority of these patients had one repeat CT infection (82.8%, *n* = 202), 14.3% (*n* = 35) had two repeat CT infections, 2.0% (*n* = 5) had three repeat CT infections, and 0.8% (*n* = 2) had four repeat CT infections.

Patients who never tested CT positive and who had multiple CT negative repeat tests within the entire study period were classified as “Patients repeatedly tested negative” (*n* = 3794). The majority of these patients (65.8%, *n* = 2497) tested CT negative twice, 20.8% (*n* = 791) had three negative CT tests, 7.6% (*n* = 288) had four negative CT tests, 2.9% (109) had five negative CT tests, and 2.9% (*n* = 109) had six to sixteen negative CT tests.

The binary outcome measure was: “repeat CT infections,” including patients with ≥2 repeat CT infections within the study period versus patients who repeatedly tested negative (reference group).

Ethics

The Medical Ethics Committee of the Maastricht University Medical Center (Maastricht, the Netherlands) approved this study (METC 2017–0251) and waived the need for patient consent. Since the retrospective data originated from regular care and were analyzed anonymously, no further informed consent for data analysis was obtained.

Statistical analyses

In our main analyses, we assessed whether the characteristics of individuals classified in the above described outcome measure were different compared to individuals...
who repeatedly tested negative (≥2 negative CT tests) using multivariable logistic regression analyses. The determinants analyzed were the initial test location (mental healthcare facilities, STI clinics, hospitals, or GPs), sex (men or women), age (< 25 years and ≥ 25 years), urbanization (rural or urban), HIV coinfection (not tested, yes, or no), and NG coinfection (not tested, yes, or no). All determinants were recorded at the time of the patient’s consultation. We noticed that 6.2% ($n = 1090$) of patients who tested for CT changed their STI care provider after their initial test (Supplementary Table S1). Therefore, the determinant “initial test location” was based on the STI care provider where the patient was initially tested.

Additional determinants were available for the STI clinic population only. Therefore, our secondary study population included only STI clinic visitors tested for CT ($n = 8007$). Additional determinants included the maximum number of sex partners in the past 6 months prior to a consultation a patient had in the entire study period (unknown, 0–1, 2–3, and ≥ 4), any urogenital symptoms during the study period (unknown, yes, or no), any proctitis during the study period (unknown, yes, or no), any oropharyngeal symptoms during the study period (unknown, yes, or no), any notifications of STI during the study period (unknown, yes, or no), and transmission group (men who have sex with women [MSW] or MSM, and women).

Baseline characteristics were tested using chi-square tests. Determinants with $P < 0.10$ in the univariable logistic regression models were included in the multivariable model. All the determinants included in the tables were associated with the outcome measure of interest in univariable analyses and were adjusted for in multivariable analyses. Odds ratios and 95% confidence intervals (CIs) were calculated and presented. All analyses were performed using the SPSS v.24 (IBM SPSS Statistics for Windows, IBM Corporation, Armonk, New York, USA). A $P$-value of < 0.05 was considered statistically significant.

**Results**

**Baseline characteristics**

The baseline characteristics of the total study population are described in Table 1. Patients with repeat CT
infections were more often diagnosed at the STI clinic (57.8% vs. 47.4%; \( p = 0.004 \)), younger than 25 years of age (51.6% vs. 39.0%; \( p < 0.001 \)), HIV positive (4.9% vs. 1.9%; \( p < 0.001 \)), and NG positive (15.6% vs. 3.4%; \( p = 0.001 \)).

CT testing and positivity in the residential population
Of the 111,162 individuals residing in the study area, 15.8% (\( n = 17,616 \)) were tested for CT and 2.0% (\( n = 2210 \)) tested positive at least once; 1.8% (\( n = 1966 \)) were diagnosed with one CT infection, and 0.2% (\( n = 244 \)) with \( \geq 2 \) CT infections. Within the individuals tested for CT (\( n = 17,616 \)), 1.4% (\( n = 244 \)) were repeatedly (\( \geq 2 \)) infected with CT. All 2210 CT patients contributed to 2505 CT infections. Of these 2505 CT infections, repeat CT infections (\( \geq 2 \) CT infections) accounted for 21.5% (\( n = 539 \)).

Characteristics of patients with repeat infections

| Overall % (n) | Repeatedly tested CT negative | Repeat CT infections | \( p \)-value |
|--------------|-------------------------------|---------------------|--------------|
| % (n)        | % (n)                         | % (n)               |              |
| Initial test location |                      |                    |              |
| Mental healthcare | 0.8 (29)                     | 0.0 (0)            | 0.004        |
| STI clinic | 47.4 (1798)                   | 57.8 (141)         |              |
| Hospital | 11.2 (425)                    | 6.1 (15)           |              |
| General practitioner | 40.6 (1542)                  | 36.1 (88)         |              |
| Sex |                      |                    |              |
| Men | 33.3 (1265)                  | 36.5 (89)         | 0.315        |
| Women | 66.7 (2529)                  | 63.5 (155)        |              |
| Age |                      |                    | \( < 0.001 \) |
| < 25 years | 39.0 (1480)                 | 51.6 (126)        |              |
| \( \geq 25 \) years | 61.0 (2314)                  | 48.4 (118)       |              |
| Urbanization |                      |                    | 0.243        |
| Rural | 30.1 (1140)                 | 33.6 (82)        |              |
| Urban | 69.9 (2652)                  | 66.4 (162)       |              |
| HIV positive |                      |                    | \( < 0.001 \) |
| Not tested | 28.9 (1096)                | 21.3 (52)        |              |
| Yes | 1.9 (72)                    | 4.9 (12)         |              |
| No | 69.2 (2626)                 | 73.8 (180)       |              |
| NG positive |                      |                    | \( < 0.001 \) |
| Not tested | 1.1 (43)                    | 0.4 (1)          |              |
| Yes | 3.4 (128)                   | 15.6 (38)        |              |
| No | 95.5 (3623)                 | 84.0 (205)       |              |

Statistically significant (\( p < 0.05 \)) associations are depicted in bold

Abbreviations: CT, Chlamydia trachomatis; NG, Neisseria gonorrhoeae; HIV, Human immunodeficiency virus; STI, sexually transmitted infection

Discussion
In this study, we included all CT consultations at STI care providers in a defined geographical area to assess whether patients repeatedly infected with CT were different to those repeatedly tested negative. Patients aged \( < 25 \) years or coinfected with NG or HIV more often had repeat CT infections and were likely at the highest risk for acquiring and transmitting CT. Those patients with
repeat CT infections accounted for 22% of all diagnosed CT infections.

A comparable study by Hsu et al. showed that 28% of all diagnosed STIs were repeat (≥2) infections [9]. They concluded that a relatively small group of patients repeatedly infected with STIs likely have a disproportionately high impact on circulating STIs within a population; the so called “core group” [9]. The authors included all relevant STIs in their case definition including repeat syphilis, NG, and CT infections. However, we believe that the “core group” theory is STI specific. For example, 76% of the NG infections are diagnosed among MSM in the Netherlands. Whereas CT infections are distributed among different transmission groups (23% of the CT diagnoses are among MSM, 50% among women, and 28% among heterosexual men) [16]. Moreover, heterosexual men, women, and MSM were equally affected by repeat CT infections arguing for population transmission instead of core group transmission (p > 0.05; Table 3). Furthermore, 16% of the residential population in our study area was tested for CT. Therefore, only a small fraction of all CT infections was likely diagnosed, leading to ongoing transmission within the population.

Repeatedly infected patients who undergo repeat tests have higher risks for transmitting and acquiring STIs. Repeat CT infections are common among patients who are retested within 1 year (up to 32%) [7, 17–19]. Retesting CT-positive patients is an effective control strategy and can be used to enhance the population-based prevention of CT [4]. Although retesting is advised in many international guidelines [2, 4, 20, 21], retesting rates remain typically low [7, 17–19].

We hypothesized that symptomatic CT patients were more likely to have repeat CT infections. Potentially patients with symptoms are members of sexual networks and at high risk for acquiring and transmitting CT. Hence, STI clinic patients with urogenital symptoms were more likely to have repeat CT infections compared to patients without these symptoms. Our study group and others observed an association between urogenital

| Table 2 | Primary analyses among the total population tested for Chlamydia trachomatis between January 2011 and July 2018 including determinants associated with repeat CT infections using patients repeatedly tested CT negative as the reference group |
|---------|-------------------------------------------------|
| Overall % (n) | 100 (17,616) |
| Initial test location | 100 (3794) |
| Mental healthcare | 100 (29) |
| STI clinic | 45.5 (8007) |
| General practitioner | 45.5 (2506) |
| Hospital | 39.6 (6979) |
| Sex | 64.0 (11,266) |
| Men | 93.4 (1265) |
| Women | 94.2 (2529) |
| Age < 25 years | 45.4 (7990) |
| ≥ 25 years | 54.6 (9626) |
| Urbanization | 68.4 (12,051) |
| Rural | 93.3 (1140) |
| Urban | 94.2 (2652) |
| HIV positive | 68.4 (12,051) |
| Not tested | 95.5 (1096) |
| Yes | 85.7 (72) |
| No | 93.6 (2626) |
| NG positive | 53.7 (9459) |
| Not tested | 97.7 (43) |
| Yes | 77.6 (128) |
| No | 94.6 (3623) |

Statistically significant (p < 0.05) associations are depicted in bold
Abbreviations: CT, Chlamydia trachomatis, NG, Neisseria gonorrhoeae; HIV, Human immunodeficiency virus; STI, sexually transmitted infection; OR, odds ratio; CI, confidence interval; Adj., adjusted
symptoms and a higher CT bacterial load. This could indicate a higher transmission potential and clinical relevance [22–24]. Furthermore, the highest CT positivity rates are found among patients notified for CT (35.2% in women, 32.8% in heterosexual men, and 22.5% in MSM) [16]. Notably, STI clinic patients notified for STIs were more often repeatedly infected with CT, implying the essential role of partner management for targeting, testing, and treating this high-risk population [25]. Therefore, STI clinics should recommend CT retesting for all CT patients independent of sex or sexual preference.

One strength of this study was that every CT consultation by all STI care providers in a defined geographical area were included to obtain insights in CT testing differences between STI care providers. Due to the inclusion of all tests by the STI clinics and medical specialists and the high coverage of GP data (81%), underestimations of CT tests seem unlikely [7]. Another strength is the timeframe of 7.5 years to partially prevent underestimations of repeat infections [9]. We excluded all positive CT tests occurring within 30 days of an earlier positive test to be able to draw accurate conclusions about patients repeatedly infected, i.e., false-positive test results within 30 days could arise due to non-viable recurrent CT [4]. The additional analyses among STI clinic visitors allowed us to assess additional determinants related to sexual behavior and draw conclusions specified for STI clinic visitors.

One limitation of the study was that information on the reasons for testing was unavailable. Such reasons

### Table 3

Secondary analyses among only the STI clinic population tested for *Chlamydia trachomatis* between January 2011 and July 2018 including determinants associated with repeat CT infections using patients repeatedly tested CT negative as the reference group.

|                         | All individuals tested for CT % (n) | Repeatedly tested CT negative % (n) | Repeat CT infections % (n) | OR (95%CI)       | Adj. OR (95%CI) |
|-------------------------|------------------------------------|------------------------------------|---------------------------|------------------|-----------------|
| **Overall % (n)**       | 100 (8007)                         | 100 (1798)                         | 100 (141)                 |                  |                 |
| **Maximum number of sex partners** |                                    |                                    |                           |                  |                 |
| Unknown                 | 2.9 (232)                          | 91.3 (21)                          | 8.7 (2)                   | 2.19 (0.44–10.81)|                  |
| 0–1                     | 25.7 (2059)                        | 95.8 (207)                         | 4.2 (9)                   |                  |                 |
| 2–3                     | 42.7 (3415)                        | 92.5 (769)                         | 7.5 (62)                  | 1.85 (0.91–3.79) |                  |
| ≥ 4                     | 28.7 (2301)                        | 92.2 (801)                         | 7.8 (68)                  | 1.95 (0.96–3.98) |                  |
| **Any urogenital symptoms** |                                    |                                    |                           |                  |                 |
| Unknown                 | 4.7 (374)                          | 94.7 (36)                          | 5.3 (2)                   | 1.14 (0.26–4.95) | 1.53 (0.28–8.29)|
| Yes                     | 53.9 (4315)                        | 91.4 (1174)                        | 8.6 (111)                 | 1.99 (1.30–3.04) | 2.17 (1.41–3.35)|
| No                      | 41.4 (3318)                        | 95.5 (588)                         | 4.5 (28)                  |                  |                 |
| **Any Proctitis**       |                                    |                                    |                           |                  |                 |
| Unknown                 | 4.7 (374)                          | 94.7 (36)                          | 5.3 (2)                   | 0.73 (0.17–3.08) |                  |
| Yes                     | 8.4 (676)                          | 89.8 (230)                         | 10.2 (113)                | 1.53 (0.98–2.40) |                  |
| No                      | 86.9 (6957)                        | 93.1 (1532)                        | 6.9 (26)                  |                  |                 |
| **Any oropharyngeal symptoms** |                                    |                                    |                           |                  |                 |
| Unknown                 | 4.7 (374)                          | 94.7 (36)                          | 5.3 (2)                   | 0.70 (0.17–2.93) |                  |
| Yes                     | 10.3 (826)                         | 92.0 (289)                         | 8.0 (25)                  | 1.12 (0.71–1.75) |                  |
| No                      | 85.0 (6807)                        | 92.8 (1473)                        | 7.2 (114)                 |                  |                 |
| **Any notification for STI** |                                    |                                    |                           |                  |                 |
| Unknown                 | 3.5 (282)                          | 95.1 (39)                          | 4.9 (2)                   | 0.98 (0.23–4.13) | 1.09 (0.21–5.66)|
| Yes                     | 14.0 (1120)                        | 81.5 (268)                         | 18.5 (61)                 | **4.35 (3.04–6.23)** | **4.55 (3.17–6.54)** |
| No                      | 82.5 (6605)                        | 95.0 (1491)                        | 5.0 (78)                  |                  |                 |
| **Transmission group**  |                                    |                                    |                           |                  |                 |
| MSW                     | 30.2 (2415)                        | 90.9 (341)                         | 9.1 (34)                  | 1.33 (0.88–2.03) |                  |
| MSM                     | 11.2 (900)                         | 93.5 (360)                         | 6.5 (25)                  | 0.93 (0.59–1.48) |                  |
| Women                   | 58.6 (4692)                        | 93.0 (1097)                        | 7.0 (82)                  |                  |                 |

Statistically significant associations (p < 0.05) are depicted in bold.

Abbreviations: CT *Chlamydia trachomatis*, NG *Neisseria gonorrhoeae*, HIV Human immunodeficiency virus, STI Sexually transmitted infection, OR Odds ratio, CI Confidence interval, Adj. Adjusted
may include financial reasons. For example, STI tests at the GP are within patients’ deductibles in healthcare insurances, whereas STI tests at the STI clinic are free of charge for risk groups (age < 25 years, MSM, and commercial sex workers) [26, 27]. Such reasons for testing could provide additional insight into whether patients were repeatedly tested or not. Furthermore, the additional determinants (sexual risk behaviors and symptoms) assessed in the STI clinic population were not available for the mental healthcare, GP, and hospital populations. We were unable to assess whether patients moved out of the study area or were repeat tested by another STI care provider out of the study area, potentially leading to an underestimation of repeat infections or repeat tests. However, we expect this potential bias to be low, since repeat testing in general at different STI care providers, such as the STI clinic and GP, is proven to be low [7, 17, 19]. A general limitation of studies using existing databases is that data are only available for the tested population, and likely a proportion of all CT infections remain undiagnosed and are not considered. However, this study is one of the few to include all tests by all care providers in one geographical area, therefore including at least almost the whole tested population.

Conclusions
Patients aged < 25 years, and patients coinfected with HIV or NG had more repeat CT infections accounting for one out of five diagnosed cases of CT. Also, patients treated at STI clinics with urogenital symptoms and notified for STIs had a greater frequency of repeat CT infections. Those patients are likely at the highest risk for transmitting and acquiring CT. Therefore, testing and retesting this group remains important to enhance CT control.

Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.1186/s12889-020-09334-9.

Additional file 1 Supplementary Table S1. Patients who changed from STI care provider after initial test, 2011–2018.

Abbreviations
CM: Chlamydia trachomatis; NG: Neisseria gonorrhoeae; MSM: Men who have sex with men; GPs: General practitioners; MUMC+: Maastricht University Medical Center; MSW: Men who have sex with women; CIs: Confidence intervals

Acknowledgements
Not applicable.

Authors’ contributions
Conceptualization: JW, ND, CH, and GvL. Methodology: JW, ND, CH, and GvL. Formal analysis: JW. Writing – Original Draft Preparation: JW. Writing – Review & Editing: JW, ND, CH, PW, and GvL. Supervision: ND, CH, and GvL. Project Administration: JW. The authors read and approved the final manuscript. Dr. Geneviève van Liere is an associate editor of BMC Public Health.

Funding
Not applicable.

Availability of data and materials
Due to the Dutch law of protection of personal information (wet bescherming personengegevens Wbp) personal data were anonymized prior to analysis. Personal data were not shared with any third party. The data used in this study are not publically available. For permission, interested researchers are required to provide their name and institution to avoid misuse of this sensitive data and to align with the Dutch law of protection of personal information. Therefore, interested researchers may contact the head of the data-archiving (Helen Sijstermans: Helen.sijstermans@ggdzl.nl) to receive the data.

Ethics approval and consent to participate
The Medical Ethics Committee of the Maastricht University Medical Center (Maastricht, the Netherlands) approved this study (METC 2017–0251) and waived the need for patient consent. Since the retrospective data originated from regular care and were analyzed anonymously, no further informed consent for data analysis was obtained.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Received: 11 March 2020 Accepted: 3 August 2020
Published online: 14 August 2020

References
1. Newman L, Rowley J, Vander Hoorn S, Wijesooriya NS, Unemo M, Low N, et al. Global estimates of the prevalence and incidence of four curable sexually transmitted infections in 2012 based on systematic review and global reporting. PLoS One. 2015;10(12):e0143304.
2. Bignell C, Unemo M, European STIGEB. 2012 European guideline on the diagnosis and treatment of gonorrhoea in adults. Int J STD AIDS. 2013;24(2):85–92.
3. Sexually Transmitted Infections in Primary Care 2013 (RCPG/BASHH) available at www.rcgp.org and www.bassh.org-guidelines. Accessed 13 Jan 2020.
4. Workowski KA. Centers for Disease Control and Prevention sexually transmitted diseases treatment guidelines. Clin Infect Dis. 2015;61(Suppl 8):579–62.
5. Hosenfeld CB, Workowski KA, Berman S, Zaidi A, Dyson J, Mosure D, et al. Repeat infection with chlamydia and gonorrhea among females: a systematic review of the literature. Sex Transm Dis. 2009;36(8):478–89.
6. Fung M, Scott KC, Kent CK, Klausner JD. Chlamydial and gonococcal reinfection among men: a systematic review of data to evaluate the need for retesting. Sex Transm Infect. 2007;83(4):304–9.
7. Wijers J, van Liere G, Hoebe C, Cals JW, Wolffs PFG, Dukers-Muijters N. Test of cure, retesting and extragenital testing practices for chlamydia trachomatis and Neisseria gonorrhoeae among general practitioners in different socioeconomic status areas: a retrospective cohort study, 2011-2016. PLoS One. 2018;13(10):e0194351.
8. Hughes G, Brady AR, Catchpole MA, Fenton KA, Rogers PA, Kinghorn GR, et al. Characteristics of those who repeatedly acquire sexually transmitted infections: a retrospective cohort study of attendees at three urban sexually transmitted disease clinics in England. Sex Transm Dis. 2001;28(7):379–86.
9. Hsu KK, Molotnikov LE, Roosevelt KA, Elder HR, Klevens RM, DeMaria A Jr, et al. Characteristics of cases with repeated sexually transmitted infections, Massachusetts, 2014-2016. Clin Infect Dis. 2018;67(1):99–104.
10. Kinghorn GR, Pyce D, Morton RS. Repeated gonorrhoea in Sheffield: the size of the problem, epidemiologic significance, and personal characteristics of repeaters. Sex Transm Dis. 1982;9(4):165–9.
11. Visser M, van Aar F, Koedijk FDH, Kampman CJJ, Heijne JCM. Repeat chlamydia trachomatis testing among heterosexual STI outpatient clinic
12. Bjekic M, Vlajinac H, Marinkovic J. Behavioural and social characteristics of subjects with repeated sexually transmitted diseases. Acta Derm Venereol. 2000;80(1):44–7.
13. Gesink DC, Sullivan AB, Miller WC, Bernstein KT. Sexually transmitted disease core theory: roles of person, place, and time. Am J Epidemiol. 2011;174(1):81–9.
14. Gotz HM, van Oeffelen LA, Hoebe C, van Benthem BH. Regional differences in chlamydia and gonorrhoeae positivity rate among heterosexual STI clinic visitors in the Netherlands: contribution of client and regional characteristics as assessed by cross-sectional surveillance data. BMJ Open. 2019;9(1):e022793.
15. Wijers J, Hoebe C, Dukers-Muijners N, Wolffs P, van Liere G. The characteristics of patients frequently tested and repeatedly infected with Neisseria gonorrhoeae. Int J Environ Res Public Health. 2020;17(5):1495.
16. Slurink I, van Aar F, Op de Coul E, Heijne J, van Wees D, Hoenderboom B, Visser M, den Daas C, Woestenberg P, Gotz H et al. Sexually transmitted infections in the Netherlands in 2018: Rijksinstituut voor Volksgezondheid en Milieu.
17. Bowring AL, Gouillou M, Guy R, Kong FY, Hocking J, Pirotta M, et al. Missed opportunities–low levels of chlamydia retesting at Australian general practices, 2008-2009. Sex Transm Infect. 2012;88(5):330–4.
18. Rose SB, Garrett SM, Stanley J, Pullon SRH. Retesting and repeat positivity following diagnosis of chlamydia trachomatis and Neisseria gonorrhoeae in New Zealand: a retrospective cohort study. BMC Infect Dis. 2017;17(1):526.
19. Dukers-Muijners NH, van Liere GA, Hoebe CJ. Re-screening Chlamydia trachomatis positive subjects: a comparison of practices between an STI clinic, general practitioners and gynaecologists. Sex Transm Infect. 2013;89(1):25–7.
20. Lanjouw E, Duburg S, de Vries HJ, Stany A, Radcliffe K, Unemo M. 2015 European guideline on the management of Chlamydia trachomatis infections. Int J STD AIDS. 2016;27(5):333–48.
21. Nwokolo NC, Dragovic B, Patel S, Tong CY, Barker G, Radcliffe K. 2015 UK national guideline for the management of infection with Chlamydia trachomatis. Int J STD AIDS. 2016;27(4):251–67.
22. Vodstrcil LA, Melver R, Huston WM, Tabrizi SN, Timms P, Hocking JS. The epidemiology of chlamydia trachomatis organism load during genital infection: a systematic review. J Infect Dis. 2015;211(10):1628–45.
23. Jalal H, Verlander NQ, Kumar N, Bentley N, Carne C, Sonnex C. Genital chlamydial infection: association between clinical features, organism genotype and load. J Med Microbiol. 2011;60(Pt 7):881–8.
24. Theunissen KA, Schipper P, Hoebe CJ, Crutzzen R, Kok G, Dukers-Muijners NH. Barriers to and facilitators of partner notification for chlamydia trachomatis among health care professionals. BMC Health Serv Res. 2014;14:647.
25. Kampman C, Koedijk F, Driessen-Hulshof H, Hautvast J, van den Broek I. Retesting young STI clinic visitors with urogenital Chlamydia trachomatis infection in the Netherlands; response to a text message reminder and reinfection rates: a prospective study with historical controls. Sex Transm Infect. 2016;92(2):124–9.
26. Gotz HM, Wolfers ME, Luijendijk A, van den Broek IV. Retesting for genital Chlamydia trachomatis among visitors of a sexually transmitted infections clinic randomized intervention trial of home- versus clinic-based recall. BMC Infect Dis. 2013;13:239.

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.